Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Fortifies Vesicare And Mirabegron; Looks For Organic Growth In Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Unlike its top rival Takeda Pharmaceuticals Co. Ltd., Astellas Pharma Inc. says it will primarily look for organic growth in emerging markets, although the Japanese major is not adverse to M&A if it finds the right opportunity

You may also be interested in...



2012 A Key Year For Astellas, Says New CEO Yoshihiko Hatanaka

Astellas is on the verge of significantly increasing its heretofore small presence in oncology in the U.S. and abroad as it, along with its partners, prepares to file one and possibly two NDAs, including for the promising prostate cancer treatment MDV3100.

2012 A Key Year For Astellas, Says New CEO Yoshihiko Hatanaka

Astellas is on the verge of significantly increasing its heretofore small presence in oncology in the U.S. and abroad as it, along with its partners, prepares to file one and possibly two NDAs, including for the promising prostate cancer treatment MDV3100.

Astellas Discontinues Development Of Factor Xa Inhibitor Darexaban

Unable to find a partner to co-develop the compound, Astellas is bowing out of the anticoagulant space.

Related Content

UsernamePublicRestriction

Register

SC142496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel